FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993691917> ?p ?o ?g. }

• W1993691917 endingPage "245" @default.
• W1993691917 startingPage "237" @default.
• W1993691917 abstract "This study is focused on therapy-related myeloid neoplasms after the most promising frontline FCR (fludarabine, cyclophosphamide, and rituximab) therapy in previously untreated chronic lymphocytic leukemia patients. A total of 28 therapy-related myeloid neoplasm patients were identified, including 19 patients from 3 well-controlled FCR frontline trials (n=426 patients), giving an estimated frequency of 4.5% (1.9–8.3%) in a follow-up period of 44 months (range 5–122 months). Clinically, therapy-related myeloid neoplasms could emerge directly from ‘prolonged myelosuppression’ after FCR (10 patients), or after achieving complete hematological recovery (n=18). The overall latency was 35 months (range 3–118 months), with the former group of 23 months and the latter 42 months (P<0.001). In all, 10 cases presented as therapy-related acute myeloid leukemia and 18 as therapy-related myelodysplastic syndromes. Abnormal cytogenetics was present in 26 of 27 (96%) patients, with frequent chromosomes 5 and 7 abnormalities. The median survival was 7 months after therapy-related myeloid neoplasms. Our results indicate that the risk of therapy-related myeloid neoplasms secondary to frontline FCR therapy may not be as high as previously reported after removing the confounding factor of previous cytotoxic exposure, but this risk increased with older age and likely growth factor co-administration. Therapy-related myeloid neoplasms after FCR therapy shares clinicopathological features with therapy-related myeloid neoplasms secondary to other alkylating agents, but has a shorter latency interval indicating possible synergetic effects of the nucleotide analog fludarabine. The fact that therapy-related myeloid neoplasms can directly emerge from ‘prolonged myelosuppression’ warrants a bone marrow examination to rule out therapy-related myeloid neoplasms in this clinical setting." @default.
• W1993691917 created "2016-06-24" @default.
• W1993691917 creator A5000027373 @default.
• W1993691917 creator A5002389397 @default.
• W1993691917 creator A5027575595 @default.
• W1993691917 creator A5055404021 @default.
• W1993691917 creator A5089295627 @default.
• W1993691917 creator A5089392140 @default.
• W1993691917 creator A5089428686 @default.
• W1993691917 date "2012-01-01" @default.
• W1993691917 modified "2023-09-30" @default.
• W1993691917 title "Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma" @default.
• W1993691917 cites W1579064339 @default.
• W1993691917 cites W1965912496 @default.
• W1993691917 cites W1968504802 @default.
• W1993691917 cites W1978324270 @default.
• W1993691917 cites W1984120550 @default.
• W1993691917 cites W1984882433 @default.
• W1993691917 cites W1987173571 @default.
• W1993691917 cites W1993976589 @default.
• W1993691917 cites W2001850157 @default.
• W1993691917 cites W2034442417 @default.
• W1993691917 cites W2038402562 @default.
• W1993691917 cites W2052679523 @default.
• W1993691917 cites W2073650549 @default.
• W1993691917 cites W2078766668 @default.
• W1993691917 cites W2080337468 @default.
• W1993691917 cites W2086624357 @default.
• W1993691917 cites W2093413750 @default.
• W1993691917 cites W2098120930 @default.
• W1993691917 cites W2113228924 @default.
• W1993691917 cites W2123103213 @default.
• W1993691917 cites W2125134816 @default.
• W1993691917 cites W2142099365 @default.
• W1993691917 cites W2161926682 @default.
• W1993691917 cites W2163974548 @default.
• W1993691917 cites W2169501466 @default.
• W1993691917 cites W2326175431 @default.
• W1993691917 cites W96780237 @default.
• W1993691917 doi "https://doi.org/10.1038/modpathol.2011.158" @default.
• W1993691917 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22080061" @default.
• W1993691917 hasPublicationYear "2012" @default.
• W1993691917 type Work @default.
• W1993691917 sameAs 1993691917 @default.
• W1993691917 citedByCount "62" @default.
• W1993691917 countsByYear W19936919172012 @default.
• W1993691917 countsByYear W19936919172013 @default.
• W1993691917 countsByYear W19936919172014 @default.
• W1993691917 countsByYear W19936919172015 @default.
• W1993691917 countsByYear W19936919172016 @default.
• W1993691917 countsByYear W19936919172017 @default.
• W1993691917 countsByYear W19936919172018 @default.
• W1993691917 countsByYear W19936919172019 @default.
• W1993691917 countsByYear W19936919172020 @default.
• W1993691917 countsByYear W19936919172021 @default.
• W1993691917 countsByYear W19936919172022 @default.
• W1993691917 countsByYear W19936919172023 @default.
• W1993691917 crossrefType "journal-article" @default.
• W1993691917 hasAuthorship W1993691917A5000027373 @default.
• W1993691917 hasAuthorship W1993691917A5002389397 @default.
• W1993691917 hasAuthorship W1993691917A5027575595 @default.
• W1993691917 hasAuthorship W1993691917A5055404021 @default.
• W1993691917 hasAuthorship W1993691917A5089295627 @default.
• W1993691917 hasAuthorship W1993691917A5089392140 @default.
• W1993691917 hasAuthorship W1993691917A5089428686 @default.
• W1993691917 hasBestOaLocation W19936919171 @default.
• W1993691917 hasConcept C126322002 @default.
• W1993691917 hasConcept C143998085 @default.
• W1993691917 hasConcept C203014093 @default.
• W1993691917 hasConcept C2776694085 @default.
• W1993691917 hasConcept C2776755627 @default.
• W1993691917 hasConcept C2777938653 @default.
• W1993691917 hasConcept C2778461978 @default.
• W1993691917 hasConcept C2778729363 @default.
• W1993691917 hasConcept C2779263901 @default.
• W1993691917 hasConcept C2779282312 @default.
• W1993691917 hasConcept C2779338263 @default.
• W1993691917 hasConcept C2780653079 @default.
• W1993691917 hasConcept C71924100 @default.
• W1993691917 hasConcept C90924648 @default.
• W1993691917 hasConceptScore W1993691917C126322002 @default.
• W1993691917 hasConceptScore W1993691917C143998085 @default.
• W1993691917 hasConceptScore W1993691917C203014093 @default.
• W1993691917 hasConceptScore W1993691917C2776694085 @default.
• W1993691917 hasConceptScore W1993691917C2776755627 @default.
• W1993691917 hasConceptScore W1993691917C2777938653 @default.
• W1993691917 hasConceptScore W1993691917C2778461978 @default.
• W1993691917 hasConceptScore W1993691917C2778729363 @default.
• W1993691917 hasConceptScore W1993691917C2779263901 @default.
• W1993691917 hasConceptScore W1993691917C2779282312 @default.
• W1993691917 hasConceptScore W1993691917C2779338263 @default.
• W1993691917 hasConceptScore W1993691917C2780653079 @default.
• W1993691917 hasConceptScore W1993691917C71924100 @default.
• W1993691917 hasConceptScore W1993691917C90924648 @default.
• W1993691917 hasIssue "2" @default.
• W1993691917 hasLocation W19936919171 @default.
• W1993691917 hasLocation W19936919172 @default.
• W1993691917 hasOpenAccess W1993691917 @default.

• next